Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · see citing works

Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer

Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722 · see citing works

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · see citing works

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · see citing works

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · see citing works

Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · see citing works

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · see citing works

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · see citing works

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467 · see citing works

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · see citing works

Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · see citing works

Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer

Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · see citing works

Cetuximab for the Treatment of Colorectal Cancer

Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · see citing works

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · see citing works

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Douillard, J., Siena, S., Cassidy, J., Tabernero, J. M., Burkes, R. L., Barugel, M. E., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,802 · see citing works

FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial

Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · see citing works

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Bokemeyer, C., Bondarenko, I., Makhson, A. M., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,629 · see citing works

Cetuximab in the treatment of colorectal cancer.

Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518 · see citing works

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431 · see citing works

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen

Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402 · see citing works

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,178 · see citing works

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167 · see citing works

FOLFOXIRI plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Treatment of Patients with Metastatic Colorectal Cancer: Updated Overall Survival and Molecular Subgroup Analyses of the Open-Label, Phase 3 TRIBE Study

Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · see citing works

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062 · see citing works

Randomized Phase III Study of Panitumumab with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared with FOLFIRI Alone as Second-Line Treatment in Patients with Metastatic Colorectal Cancer

Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005 · see citing works

Ramucirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study

Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952 · see citing works

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

Cassidy, J., Clarke, S. J., Díaz‐Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S. L., Lichinitser, M., Yang, T., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 861 · see citing works

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H., Venook, A. P., Heinemann, V., Cutsem, E. V., Pignon, J., Tabernero, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 837 · see citing works

Regorafenib plus Best Supportive Care versus Placebo plus Best Supportive Care in Asian Patients with Previously Treated Metastatic Colorectal Cancer (CONCUR): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Li, J., Qin, S., Xu, R., Yau, T. C. C., Ma, B., Pan, H., Xu, J., Bai, Y., Chi, Y., Wang, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70156-7 · Cited by 813 · see citing works

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O. M., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 798 · see citing works

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789 · see citing works

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783 · see citing works

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775 · see citing works

Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers

Samowitz, W. S., Sweeney, C., Herrick, J. S., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0404 · Cited by 737 · see citing works

Extension of the Frontiers of Surgical Indications in the Treatment of Liver Metastases From Colorectal Cancer

Minagawa, M., Makuuchi, M., Torzilli, G., Takayama, T., Kawasaki, S., Kosuge, T., Yamamoto, J., & Imamura, H. (2000) · Annals of Surgery · doi:10.1097/00000658-200004000-00006 · Cited by 661 · see citing works

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 637 · see citing works

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L. R., Hecht, J. R., Yu, H., Oliner, K. S., & Go, W. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2473 · Cited by 632 · see citing works

Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer

Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606 · see citing works

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · see citing works

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Venook, A. P., Niedzwiecki, D., Lenz, H., Innocenti, F., Mahoney, M. R., O’Neil, B. H., Shaw, J. E., Polite, B. N., Höchster, H. S., Atkins, J. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba3 · Cited by 428 · see citing works

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

Primrose, J. M., Falk, S. J., Finch-Jones, M., Valle, J. W., O'Reilly, D. A., Siriwardena, A. K., Hornbuckle, J., Peterson, M. C., Rees, M., Iveson, T. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70105-6 · Cited by 425 · see citing works

An updated Asia Pacific Consensus Recommendations on colorectal cancer screening

Sung, J. J. �., Ng, S. C., Chan, F. K. L., Chiu, H., Kim, H. S., Matsuda, T., Ng, S. S. M., Lau, J. Y. W., Zheng, S. S., Adler, S. N., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306503 · Cited by 406 · see citing works

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

Yokota, T., Ura, T., Shibata, N., Takahari, D., Shitara, K., Nomura, M., Kondo, C., Mizota, A., Utsunomiya, S., Muro, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.19 · Cited by 399 · see citing works

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases

Ye, L., Liu, T., Ren, L., Wei, Y., Zhu, D., Zai, S.-Y., Ye, Q., Yu, Y., Xu, B., Qin, X.-Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8308 · Cited by 392 · see citing works

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326 · see citing works

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

Gavin, P. G., Colangelo, L. H., Fumagalli, D., Tanaka, N., Remillard, M. Y., Yothers, G., Kim, C., Taniyama, Y., Kim, S. I., Choi, H. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0605 · Cited by 320 · see citing works

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Yamazaki, K., Nagase, M., Tamagawa, H., Ueda, S., Tamura, T., Murata, K., Nakajima, T. E., Baba, E., Tsuda, M., Moriwaki, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw206 · Cited by 270 · see citing works

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015

Allegra, C. J., Rumble, R. B., Hamilton, S. R., Mangu, P. B., Roach, N., Hantel, A., & Schilsky, R. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9674 · Cited by 267 · see citing works

Effects of Preanalytical Variables on the Detection of Proteins by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Tissue

Engel, K. B., & Moore, H. M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0702-rair.1 · Cited by 263 · see citing works

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

Bokemeyer, C., Köhne, C.-H., Ciardiello, F., Lenz, H.-J., Heinemann, V., Klinkhardt, U., Beier, F., Duecker, K., van Krieken, J. H., & Tejpar, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.007 · Cited by 256 · see citing works

An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013

Katanoda, K., Hori, M., Matsuda, T., Shibata, A., Nishino, Y., Hattori, M., Soda, M., Ioka, A., Sobue, T., & Nishimoto, H. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv002 · Cited by 250 · see citing works

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Yamada, Y., Takahari, D., Matsumoto, H., Baba, H., Nakamura, M., Yoshida, K., Yoshida, M., Iwamoto, S., Shimada, K., Komatsu, Y., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70490-x · Cited by 250 · see citing works

Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions.

Kato, T., Yasui, K., Hirai, T., et al. (2003) · PubMed · doi:10.1097/01.dcr.0000089106.71914.00 · Cited by 237 · see citing works

Adjustment of children and adolescents to parental cancer: Parents' and children's perspectives

Welch, A. S., Wadsworth, M. E., & Compas, B. E. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7 · Cited by 217 · see citing works

Stereotactic Body Radiotherapy for Oligometastatic Lung Tumors

Norihisa, Y., Nagata, Y., Takayama, K., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.01.002 · Cited by 202 · see citing works

Analysis of KRAS / NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181 · see citing works

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

Kuboki, Y., Nishina, T., Shinozaki, E., Yamazaki, K., Shitara, K., Okamoto, W., Kajiwara, T., Matsumoto, T., Tsushima, T., Mochizuki, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30425-4 · Cited by 180 · see citing works

Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer

Takeda, A., Kunieda, E., Ohashi, T., Aoki, Y., Koike, N., & Takeda, T. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.033 · Cited by 163 · see citing works

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

Karapetis, C. S., Jonker, D. J., Daneshmand, M., Hanson, J. E. L., O'Callaghan, C. J., Marginean, C. E., Zalcberg, J. R., Simes, J. R., Moore, M. J., Tebbutt, N. C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0606 · Cited by 158 · see citing works

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer

Kim, M. J., Lee, H. S., Kim, J. H., Kim, Y. J., Kwon, J. H., Lee, J., Bang, S., Park, K. U., Kim, D., Kang, S., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-347 · Cited by 141 · see citing works

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Stintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 139 · see citing works

BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics

Phipps, A. I., Buchanan, D. D., Makar, K. W., Burnett‐Hartman, A. N., Coghill, A. E., Passarelli, M. N., Baron, J. A., Ahnen, D. J., Win, A. K., Potter, J. D., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0674 · Cited by 131 · see citing works

Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival

Sawai, H., Yasuda, A., Ochi, N., Ma, J., Matsuo, Y., Wakasugi, T., Takahashi, H., Funahashi, H., Sato, M., & Takeyama, H. (2008) · BMC Gastroenterology · doi:10.1186/1471-230x-8-56 · Cited by 129 · see citing works

Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial

Hasegawa, K., Saiura, A., Takayama, T., Miyagawa, S., Yamamoto, J., Ijichi, M., Teruya, M., Yoshimi, F., Kawasaki, S., Koyama, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162400 · Cited by 129 · see citing works

A combined oncogenic pathway signature of <i>BRAF</i> , <i>KRAS</i> and <i>PI3KCA</i> mutation improves colorectal cancer classification and cetuximab treatment prediction

Tian, S., Simon, I., Moreno, V., Roepman, P., Tabernero, J., Snel, M., van't Veer, L., Salazar, R., Bernards, R., & Capella, G. (2013) · Gut · doi:10.1136/gutjnl-2012-302423 · Cited by 128 · see citing works

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

Hong, Y. S., Park, Y. S., Lim, H. Y., Lee, J., Kim, T. W., Kim, K., Kim, S. Y., Baek, J. Y., Kim, J. H., Lee, K., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70363-7 · Cited by 127 · see citing works

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Yoshino, T., Komatsu, Y., Yamada, Y., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0154-x · Cited by 123 · see citing works

Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway

Nosho, K., Igarashi, H., Nojima, M., Ito, M., Maruyama, R., Yoshii, S., Naito, T., Sukawa, Y., Mikami, M., Sumioka, W., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt374 · Cited by 112 · see citing works

Prognostic Factors of Peritoneal Metastases from Colorectal Cancer following Cytoreductive Surgery and Perioperative Chemotherapy

Yonemura, Y., Canbay, E., & Ishibashi, H. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/978394 · Cited by 110 · see citing works

Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor

Fujiyoshi, K., Yamamoto, G., Takenoya, T., TAKAHASHI, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11313 · Cited by 108 · see citing works

Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers

Arber, D. A. (2002) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200206000-00015 · Cited by 107 · see citing works

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

Kawazoe, A., Shitara, K., Fukuoka, S., Kuboki, Y., Bando, H., Okamoto, W., Kojima, T., Fuse, N., Yamanaka, T., Doi, T., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1276-z · Cited by 106 · see citing works

Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms

Satoh, T., Ura, T., Yamada, Y., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02030.x · Cited by 103 · see citing works

Irinotecan Pharmacogenomics

Marsh, S., & Hoskins, J. M. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.95 · Cited by 103 · see citing works

Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

Stintzing, S., Jung, A., Rossius, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Al‐Batran, S., Vehling‐Kaiser, U., Heintges, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.445 · Cited by 97 · see citing works

Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety

Luo, H., Li, Y., Wang, W., Wang, Z. Q., Yuan, X., Ma, D., Wang, F., Zhang, D. S., Lin, D., Lin, Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw101 · Cited by 92 · see citing works

Treatment of Pulmonary Colorectal Metastases by Radiofrequency Ablation

Petre, E. N., Jia, X., Thornton, R. H., Sofocleous, C. T., Alago, W., Kemeny, N. E., & Solomon, S. B. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.07.003 · Cited by 89 · see citing works

MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer

Xie, T., Huang, M., Wang, Y., Wang, L., Chen, C., & Chu, X. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000452525 · Cited by 89 · see citing works

Utility of KRAS mutation detection using circulating cell‐free DNA from patients with colorectal cancer

Yamada, T., Iwai, T., Takahashi, G., Kan, H., Koizumi, M., Matsuda, A., Shinji, S., Yamagishi, A., Yokoyama, Y., Tatsuguchi, A., et al. (2016) · Cancer Science · doi:10.1111/cas.12959 · Cited by 86 · see citing works

Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.

Tsuji, T., Hidaka, S., Sawai, T., et al. (2003) · PubMed · Cited by 80 · see citing works

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians

Cheng, L., Li, M., Hu, J. Y., Ren, W., Xie, L., Sun, Z., Liu, B., Xu, G., Dong, X., & Qian, X. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2382-3 · Cited by 77 · see citing works

Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012

Ku, G. Y., Tan, I. B., Yau, T. C. C., Boku, N., Laohavinij, S., Cheng, A., Kang, Y., & Lopes, G. D. L., Jr. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70424-2 · Cited by 76 · see citing works

Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity.

Kouwaki, M., Hamajima, N., Sumi, S., et al. (1998) · PubMed · Cited by 75 · see citing works

High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases

Fujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.5323 · Cited by 74 · see citing works

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer

Matsusaka, S., Suenaga, M., Mishima, Y., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01926.x · Cited by 72 · see citing works

A Randomized Phase II/III Trial Comparing Hepatectomy Followed by mFOLFOX6 with Hepatectomy Alone as Treatment for Liver Metastasis from Colorectal Cancer: Japan Clinical Oncology Group Study JCOG0603

Kanemitsu, Y., Kato, T., Shimizu, Y., et al. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp035 · Cited by 69 · see citing works

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6498 · Cited by 69 · see citing works

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

Kim, T. W., Elme, A., Kusić, Z., Park, J. O., Udrea, A. A., Kim, S. Y., Ahn, J. B., Villalobos-Valencia, R., Krishnan, S., Bilic, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.309 · Cited by 67 · see citing works

Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer

Price, T. J., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Guan, X., & Peeters, M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.010 · Cited by 66 · see citing works

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐ WJOG 6210G

Shitara, K., Yonesaka, K., Denda, T., Yamazaki, K., Moriwaki, T., Tsuda, M., Takano, T., Okuda, H., Nishina, T., Sakai, K., et al. (2016) · Cancer Science · doi:10.1111/cas.13098 · Cited by 66 · see citing works

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.308 · Cited by 65 · see citing works

BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

Chen, J., Guo, F., Shi, X., Zhang, L., Zhang, A., Jin, H., & He, Y. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-802 · Cited by 64 · see citing works

Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors

Wada, H., Takai, Y., Nemoto, K., & Yamada, S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.08.012 · Cited by 63 · see citing works

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer

Takahashi, N., Yamada, Y., Furuta, K., Honma, Y., Iwasa, S., Takashima, A., Kato, K., Hamaguchi, T., & Shimada, Y. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.230 · Cited by 62 · see citing works

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study

Yoshino, T., Muro, K., Yamaguchi, K., Nishina, T., Denda, T., Kudo, T., Okamoto, W., Taniguchi, H., Akagi, K., Kajiwara, T., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.007 · Cited by 62 · see citing works

Stereotactic Body Radiation Therapy Using Three Fractions for Isolated Lung Recurrence from Colorectal Cancer

Kim, M. S., Yoo, S. Y., Cho, C. K., et al. (2009) · Oncology · doi:10.1159/000201932 · Cited by 62 · see citing works

Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung

Oh, D., Ahn, Y. C., Seo, J. M., Shin, E., Park, H. C., Lim, D. H., & Pyo, H. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.681698 · Cited by 59 · see citing works

Colorectal cancer mortality in Hong Kong of China, Japan, South Korea, and Singapore

Shin, A. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i7.979 · Cited by 59 · see citing works

A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer

Muro, K., Yoshino, T., Doi, T., Shirao, K., Takiuchi, H., Hamamoto, Y., Watanabe, H., Yang, B.-B., & Asahi, D. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp016 · Cited by 59 · see citing works

Dihydropyrimidine Dehydrogenase Activity in 150 Healthy Japanese Volunteers and Identification of Novel Mutations

Ogura, K., Ohnuma, T., Minamide, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0217 · Cited by 58 · see citing works

Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery

Ng, S. B. H., Chua, C., Ng, M., Gan, A., Poon, P., Teo, M., Fu, C., Leow, W., Lim, K., Chung, A., et al. (2017) · Scientific Reports · doi:10.1038/srep40737 · Cited by 55 · see citing works

HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy

Takegawa, N., & Yonesaka, K. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.03.001 · Cited by 55 · see citing works

A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer

Cao, R., Zhang, S., Ma, D., & Hu, L. (2014) · Medical Oncology · doi:10.1007/s12032-014-0325-9 · Cited by 53 · see citing works

Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms

Okuyama, Y., Hazama, S., Nozawa, H., Kobayashi, M., Takahashi, K. P., Fujikawa, K., Kato, T., Nagata, N., Kimura, H., Oba, K., et al. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr001 · Cited by 53 · see citing works

High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer

Tan, I. B., Malik, S., Ramnarayanan, K., McPherson, J. R., Ho, D. L., Suzuki, Y., Ng, S. B. H., Su, Y., Lim, K. H., Koh, D., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0589-1 · Cited by 50 · see citing works

A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis.

Yamaguchi, T., Mori, T., Takahashi, K., et al. (2008) · PubMed · Cited by 48 · see citing works

Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients

Kumamoto, K., Ishibashi, K., Okada, N., Tajima, Y., Kuwabara, K., KUMAGAI, Y., Baba, H., Haga, N., & Ishida, H. (2013) · Oncology Letters · doi:10.3892/ol.2013.1467 · Cited by 48 · see citing works

KRAS mutational status in Japanese patients with colorectal cancer: Results from a nationwide, multicenter, cross-sectional study

Watanabe, T., Yoshino, T., Uetake, H., Yamazaki, K., Ishiguro, M., Kurokawa, T., Saijo, N., Ohashi, Y., & Sugihara, K. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt062 · Cited by 46 · see citing works

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit

Bando, H., Yoshino, T., Shinozaki, E., Nishina, T., Yamazaki, K., Yamaguchi, K., Yuki, S., Kajiura, S., Fujii, S., Yamanaka, T., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-405 · Cited by 46 · see citing works

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy

Akiyama, Y., Fujita, K., Nagashima, F., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn645 · Cited by 46 · see citing works

Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes

Sasaki, K., Margonis, G. A., Andreatos, N., Kim, Y., Wilson, A., Gani, F., Amini, N., & Pawlik, T. M. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.06.098 · Cited by 44 · see citing works

Transcatheter Arterial Chemoembolization Using Cisplatin Powder Mixed with Degradable Starch Microspheres for Colorectal Liver Metastases after FOLFOX Failure: Results of a Phase I/II Study

Nishiofuku, H., Tanaka, T., Matsuoka, M., Otsuji, T., Anai, H., Sueyoshi, S., Inaba, Y., Koyama, F., Sho, M., Nakajima, Y., et al. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.09.010 · Cited by 43 · see citing works

Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence

Mima, K., Beppu, T., Chikamoto, A., et al. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0471-z · Cited by 43 · see citing works

Japanese Society of Medical Oncology Clinical Guidelines: RAS ( KRAS / NRAS ) mutation testing in colorectal cancer patients

Taniguchi, H., Yamazaki, K., Yoshino, T., Muro, K., Yatabe, Y., Watanabe, T., Ebi, H., Ochiai, A., Baba, E., & Tsuchihara, K. (2015) · Cancer Science · doi:10.1111/cas.12595 · Cited by 43 · see citing works

Stereotactic body radiotherapy for pulmonary metastases

Inoue, T., Oh, R., Shiomi, H., et al. (2013) · Strahlentherapie und Onkologie · doi:10.1007/s00066-012-0290-1 · Cited by 39 · see citing works

Improved survival using multi-modality therapy in patients with lung metastases from colorectal cancer: A preliminary study

Inoue, Y., Miki, C., Hiro, J., et al. (2005) · Oncology Reports · doi:10.3892/or.14.6.1571 · Cited by 38 · see citing works

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

Soeda, H., Shimodaira, H., Watanabe, M., Suzuki, T., Gamoh, M., Mori, T., Komine, K., Iwama, N., Kato, S., & Ishioka, C. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0422-8 · Cited by 37 · see citing works

Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines

Tahara, M., Shirao, K., Boku, N., Yamaguchi, K., Komatsu, Y., Inaba, Y., Arai, T., Mizunuma, N., Satoh, T., Takiuchi, H., et al. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn102 · Cited by 35 · see citing works

An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer

Poulin-Costello, M., Azoulay, L., Cutsem, E. V., Peeters, M., Siena, S., & Wolf, M. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0271-z · Cited by 34 · see citing works

A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer

Kim, K., Kim, H.-S., Sym, S. J., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2161-6 · Cited by 33 · see citing works

Optimal fixation for total preanalytic phase evaluation in pathology laboratories. A comprehensive study including immunohistochemistry, DNA , and mRNA assays

Sato, M., Kojima, M., Nagatsuma, A. K., et al. (2014) · Pathology International · doi:10.1111/pin.12164 · Cited by 32 · see citing works

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients

Nishina, T., Takano, Y., Denda, T., Yasui, H., Takeda, K., Ura, T., Esaki, T., Okuyama, Y., Kondo, K., Takahashi, Y., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt127 · Cited by 31 · see citing works

Intraoperative thermal ablation therapy for small colorectal metastases to the liver.

Ogata, Y., Uchida, S., Hisaka, T., et al. (2008) · PubMed · Cited by 31 · see citing works

Does “Conversion Chemotherapy” Really Improve Survival in Metastatic Colorectal Cancer Patients with Liver‐Limited Disease?

Kataoka, K., Kanazawa, A., Iwamoto, S., et al. (2013) · World Journal of Surgery · doi:10.1007/s00268-013-2305-1 · Cited by 29 · see citing works

Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

Horita, Y., Yamada, Y., Kato, K., Hirashima, Y., Akiyoshi, K., Nagashima, K., Nakajima, T. E., Hamaguchi, T., & Shimada, Y. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0331-2 · Cited by 29 · see citing works

TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study

Yoshino, T., Uetake, H., Fujita, N., Furuta, T., Katori, J., Hara, N., & Muro, K. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.04.004 · Cited by 29 · see citing works

Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence

Inoue, T., Katoh, N., Onimaru, R., & Shirato, H. (2012) · Pulmonary Medicine · doi:10.1155/2012/369820 · Cited by 28 · see citing works

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

Geva, R., Vecchione, L., Kalogeras, K. T., Jensen, B. V., Lenz, H., Yoshino, T., Páez, D., Montagut, C. O., Souglakos, J., Cappuzzo, F., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-307234 · Cited by 28 · see citing works

Radiofrequency Ablation Combined with Hepatic Arterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Liver Metastasis from Colorectal Cancer: A Prospective Multicenter Study

Yamakado, K., Inaba, Y., Sato, Y., Yasumoto, T., Hayashi, S., Yamanaka, T., Nobata, K., Takaki, H., & Nakatsuka, A. (2016) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-016-1547-3 · Cited by 27 · see citing works

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer

Yoshino, T., Yamazaki, K., Yamaguchi, K., Doi, T., Boku, N., Machida, N., Onozawa, Y., Asayama, M., Fujino, T., & Ohtsu, A. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9895-6 · Cited by 26 · see citing works

Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.

Yoshino, T., Yamazaki, K., Gotoh, M., Nasroulah, F., Gao, L., Yoshizuka, N., & Ohtsu, A. (2015) · PubMed · Cited by 25 · see citing works

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

Kishiki, T., Ohnishi, H., Masaki, T., Ohtsuka, K., Ohkura, Y., Furuse, J., Watanabe, T., & Sugiyama, M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2401-4 · Cited by 25 · see citing works

Hepatic Arterial Infusion of 5-Fluorouracil for Patients With Liver Metastases From Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter, Retrospective Analysis

Nishiofuku, H., Tanaka, T., Aramaki, T., Boku, N., Inaba, Y., Sato, Y., Matsuoka, M., Otsuji, T., Arai, Y., & Kichikawa, K. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.044 · Cited by 25 · see citing works

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Cheng, A., Cornelio, G. H., Shen, L., Price, T. J., Yang, T., Chung, I. J., Guang-hai, D., Lin, J.-K., Sharma, A., Yeh, K., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.08.005 · Cited by 25 · see citing works

Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer

You, Y. N., Changchien, C., Huang, J., & Ng, K. (2005) · International Journal of Colorectal Disease · doi:10.1007/s00384-005-0782-x · Cited by 24 · see citing works

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

Nakayama, I., Shinozaki, E., Matsushima, T., Wakatsuki, T., Ogura, M., Ichimura, T., Ozaka, M., Takahari, D., Suenaga, M., Chìn, K., et al. (2017) · BMC Cancer · doi:10.1186/s12885-016-2994-6 · Cited by 24 · see citing works

mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109)

Geißler, M., Martens, U. M., Knorrenschield, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.002 · Cited by 24 · see citing works

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies

Takahashi, N., Iwasa, S., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.74 · Cited by 22 · see citing works

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

Soeda, H., Shimodaira, H., Gamoh, M., Ando, H., Isobe, H., Suto, T., Takahashi, S. I., Kakudo, Y., Amagai, K., Mori, T., et al. (2014) · Oncology · doi:10.1159/000360989 · Cited by 21 · see citing works

Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer

Phua, L. C., Ng, H. W., Yeo, A. H. L., Chen, E., Lo, M., Cheah, P. Y., Chan, E. C. Y., Koh, P. K., & Ho, H. K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3560 · Cited by 21 · see citing works

mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)

Geißler, M., Klingler, T., Riera-Knorrenschield, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy149.023 · Cited by 21 · see citing works

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

Stein, A., Atanackovic, D., Hildebrandt, B., Stübs, P., Brugger, W., Hapke, G., Steffens, C.-C., Illerhaus, G., Bluemner, E., Stöhlmacher, J., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.299 · Cited by 19 · see citing works

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer

Yonesaka, K., Takegawa, N., Satoh, T., Ueda, H., Yoshida, T., Takeda, M., Shimizu, T., Chiba, Y., Okamoto, I., Nishio, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143132 · Cited by 19 · see citing works

A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study)

Hamamoto, Y., Yamaguchi, T., Nishina, T., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0159 · Cited by 18 · see citing works

Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus

Cheng, A., Li, J., Vaid, A. K., Ma, B. B. Y., Teh, C. S. C., Ahn, J. B., Bello, M. D. G., Charoentum, C., Chen, L., Lopes, G. D. L., Jr., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.004 · Cited by 17 · see citing works

Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study

Takatsuki, M., Tokunaga, S., Uchida, S., et al. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.11.007 · Cited by 17 · see citing works

Fragment c gamma receptor gene polymorphisms and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians

Iwasaki, M., Shimada, N., Kasuga, Y., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1109-3 · Cited by 16 · see citing works

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

Kotaka, M., Xu, R., Muro, K., et al. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0166-3 · Cited by 16 · see citing works

Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial

Sakamoto, J., Hamashima, H., Suzuki, H., et al. (2003) · Oncology Reports · doi:10.3892/or.10.5.1081 · Cited by 14 · see citing works

Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC).

Komatsu, Y., Muro, K., Yamaguchi, K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.721 · Cited by 14 · see citing works

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

Komatsu, Y., Ishioka, C., Shimada, K., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1630-1 · Cited by 14 · see citing works

Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab

Kuramochi, H., Ando, M., Itabashi, M., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3255-3 · Cited by 14 · see citing works

Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer.

Yonesaka, K., Satoh, T., Ueda, S., Yoshida, T., Takeda, M., Shimizu, T., Okamoto, I., Nishio, K., Tamura, T., & Nakagawa, K. (2015) · PubMed · Cited by 13 · see citing works

Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.

Ohtsu, A., Yoshino, T., Wahba, M. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.646 · Cited by 13 · see citing works

Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer.

Otsuka, K., Imai, H., Soeda, H., et al. (2013) · PubMed · Cited by 12 · see citing works

Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.

Arakawa, Y., Shimada, M., Utsunomiya, T., et al. (2014) · PubMed · Cited by 12 · see citing works

The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)

Nakayama, G., Uehara, K., Ishigure, K., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1948-1 · Cited by 12 · see citing works

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

Hong, Y. S., Lee, J., Kim, K., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9853-3 · Cited by 12 · see citing works

Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure

Sato, Y., Inaba, Y., Ura, T., et al. (2017) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-016-9915-4 · Cited by 12 · see citing works

Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer

Yoshino, T., Uetake, H., Tsuchihara, K., Shitara, K., Yamazaki, K., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.001 · Cited by 12 · see citing works

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

Suenaga, M., Mizunuma, N., Matsusaka, S., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s80449 · Cited by 11 · see citing works

Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation

Kishiki, T., Ohnishi, H., Masaki, T., Ohtsuka, K., Ohkura, Y., Furuse, J., Sugiyama, M., & Watanabe, T. (2014) · Oncology Reports · doi:10.3892/or.2014.3179 · Cited by 11 · see citing works

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study

Tezuka, T., Hamada, C., Ishida, H., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9982-3 · Cited by 11 · see citing works

Combination of O6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy

Nakajima, T. E., Yamada, Y., Shimoda, T., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.11.010 · Cited by 11 · see citing works

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

Tsutsumi, S., Ishibashi, K., Uchida, N., et al. (2012) · Oncology · doi:10.1159/000337992 · Cited by 10 · see citing works

A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer

Okita, N. T., Esaki, T., Baba, E., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9779-1 · Cited by 10 · see citing works

TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer

Kim, T. W., Shen, L., Xu, J., Sriuranpong, V., Pan, H., Xu, R., Han, S., Liu, T., Park, Y. S., Shir, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw370.14 · Cited by 10 · see citing works

Randomized phase II study of panitumumab (Pmab) + irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G.

Sugimoto, N., Sakai, D., Tamura, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.661 · Cited by 9 · see citing works

Application of ultrasound for tissue fixation: Combined use with microwave to enhance the effect of chemical fixation.

Yasuda, K., Yamashita, S., Shiozawa, M., et al. (1992) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.25.237 · Cited by 8 · see citing works

Validation and Modification of the Japanese Classification System for Liver Metastases from Colorectal Cancer: A Multi-institutional Study

Study Group for Liver Metastasis projected by the Japanese Society for Cancer of the Colon and Rectum (JSCCR), Shinto, E., Takahashi, K., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4470-y · Cited by 8 · see citing works

Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer

Takahashi, N., Yamada, Y., Taniguchi, H., Honma, Y., Iwasa, S., Kato, K., Hamaguchi, T., & Shimada, Y. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.05.004 · Cited by 7 · see citing works

Phase III Recourse Trial of Tas-102 Vs. Placebo, with Best Supportive Care (Bsc), in Patients (Pts) with Metastatic Colorectal Cancer (Mcrc) Refractory to Standard Therapies

Cutsem, E. V., Ohtsu, A., Falcone, A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.11 · Cited by 7 · see citing works

Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)

Nishi, T., Hamamoto, Y., Nagase, M., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4532 · Cited by 7 · see citing works

LBA-05 First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial

Qin, S., Xu, J., Wang, L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw237.05 · Cited by 7 · see citing works

BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

Huijberts, S. C. F. A., Schellens, J. H. M., Élez, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.043 · Cited by 7 · see citing works

Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.

Ohtsu, A., Yoshino, T., Wahba, M. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3564 · Cited by 7 · see citing works

Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer

The Singapore Cancer Network (SCAN) Colorectal Cancer Systemic Therapy Workgroup (2015) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v44n10p379 · Cited by 7 · see citing works

Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer

Koda, K., Miyauchi, H., Kosugi, C., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11105 · Cited by 6 · see citing works

Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency

Remón, J., & Soria, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw553 · Cited by 6 · see citing works

Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

Komatsu, Y., Takashima, A., Denda, T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.001 · Cited by 6 · see citing works

A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer

Wang, G., Ye, Y., Zhang, X., et al. (2015) · Medical Oncology · doi:10.1007/s12032-015-0566-2 · Cited by 5 · see citing works

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer

Kim, D., Hong, Y. S., Kim, J. E., Kim, K., Lee, J., Chun, S., Kim, J., Jang, S. J., & Kim, T. W. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.069 · Cited by 5 · see citing works

XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI

Suzuki, K., Kato, T., Muto, Y., et al. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.306 · Cited by 4 · see citing works

BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC.

Huijberts, S. C. F. A., Schellens, J. H. M., Fakih, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps3622 · Cited by 4 · see citing works

A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).

Nakamura, M., Kim, T. W., Xu, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.681 · Cited by 3 · see citing works

A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).

Satoh, T., Denda, T., Hamaguchi, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.707 · Cited by 3 · see citing works

The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)—GI-SCREEN 2013-01-CRC sub-study.

Kajiwara, T., Shitara, K., Denda, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3573 · Cited by 3 · see citing works

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Suenaga, M., Nishina, T., Mizunuma, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1175-3 · Cited by 2 · see citing works

2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study

Tsuji, Y., Yamazaki, K., Oba, M. S., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31088-7 · Cited by 1 · see citing works

Primary efficacy results and clinical impact of UGT1A1 genotype on safety from a Phase II study of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: The QUATTRO study

Bando, H., Kato, T., Yoshino, T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.105 · Cited by 1 · see citing works

Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study.

Tsuji, Y., Yamazaki, K., Oba, M. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e14616 · Cited by 1 · see citing works

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · see citing works

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225 · see citing works

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178 · see citing works

The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer

Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73 · see citing works

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer

Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022) · Cancers · doi:10.3390/cancers14194874 · Cited by 62 · see citing works

Methylation-Based Therapies for Colorectal Cancer

Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57 · see citing works

Current and emerging concepts for systemic treatment of metastatic colorectal cancer

Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39 · see citing works

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer

Osumi, H., Takashima, A., Ooki, A., Yoshinari, Y., Wakatsuki, T., Hirano, H., Nakayama, I., Okita, N., Sawada, R., Ouchi, K., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101718 · Cited by 16 · see citing works

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: Results of a systematic review and meta-analysis

Yoshino, T., Taieb, J., Kuboki, Y., Pfeiffer, P., Kumar, A., & Hochster, H. S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146137 · Cited by 12 · see citing works

Ramucirumab in the second-line treatment of metastatic colorectal cancer: A narrative review of literature from clinical trials

Chen, C.-P., Ke, T.-W., Cheng, R., & Wang, J.-Y. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-608 · Cited by 11 · see citing works

Net Direct Reimbursement of New Rural Cooperative Medical Scheme

Zhao, H. (2011) · Hospital Administration Journal of Chinese People's Liberation Army

The impending reimbursement revolution: how to prepare for future APN reimbursement.

Kennerly, S. M. (2007) · PubMed · Cited by 5 · see citing works

HT4 ASSESSMENT OF THE IMPACT OF FRENCH ATUS ON HAS REIMBURSEMENT DECISIONS

Paul, K., Rubinstein, J., Gupta, J., et al. (2020) · Value in Health · doi:10.1016/j.jval.2020.04.034

Brachytherapy Reimbursement: The Past Present and Future

Eggleston, S. (2015) · Brachytherapy · doi:10.1016/j.brachy.2015.02.247

Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries

Govaerts, L., Simoens, S., Dyck, W. V., et al. (2020) · Value in Health · doi:10.1016/j.jval.2020.01.013 · Cited by 20 · see citing works